首页> 外文会议>Falk Liver Week >Mechanisms of action of ursodeoxycholic acid in cholestasis
【24h】

Mechanisms of action of ursodeoxycholic acid in cholestasis

机译:胆囊中熊毒胆酸的作用机制

获取原文

摘要

Uisodeoxycholic acid (UDCA: 3a,7p-dihydroxy-5(3-cholanoic acid) is a dihydroxy bile acid which is used for the treatment of chronic cholestatic liver diseases such as primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC)1"5. UDCA is a physiological constituent of human bile, albeit in low amounts of 1-3% of total bile acids. In the Western literature the beneficial effects of UDCA on serum liver tests in cholestatic disorders were first reported less than 20 years ago6"8, but effects of UDCA treatment in liver disease were published earlier in Japan. In Chinese traditional medicine UDCA was used as a remedy for liver diseases in the form of dried black bear's bile9, in which UDCA constitutes the predominant bile acid (about 50-60% of total bile acids).
机译:亚脱氧胆酸(UDCA:3A,7P-二羟基-5(3-胆乙酸)是一种二羟基胆汁酸,用于治疗慢性胆汁淤积肝病,如原发性胆汁肝硬化(PBC)或原发性硬化性胆管炎(PSC)1 “5. UDCA是人胆的生理成分,尽管含量为1-3%的总胆汁酸。在西方文学中,UDCA对胆管疾病血清肝脏试验的有益作用首先报道了不到20年前的呼吸紊乱“8,但肝脏疾病中的UDCA治疗的影响在日本之前公布。在中国传统医学中,UDCA被用作干黑熊的胆汁形式的肝脏疾病的补救措施,其中UDCA构成了主要的胆汁酸(约50 -60%的总胆汁酸)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号